Jilin Aodong Pharmaceutical Group Co., Ltd.

SZSE:000623 Stock Report

Market Cap: CN¥21.4b

Jilin Aodong Pharmaceutical Group Future Growth

Future criteria checks 3/6

Jilin Aodong Pharmaceutical Group is forecast to grow earnings at 38.1% per annum. EPS is expected to grow by 36.7% per annum.

Key information

38.1%

Earnings growth rate

36.7%

EPS growth rate

Pharmaceuticals earnings growth18.9%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updated07 Oct 2024

Recent future growth updates

No updates

Recent updates

We Think That There Are More Issues For Jilin Aodong Pharmaceutical Group (SZSE:000623) Than Just Sluggish Earnings

Nov 06
We Think That There Are More Issues For Jilin Aodong Pharmaceutical Group (SZSE:000623) Than Just Sluggish Earnings

Market Might Still Lack Some Conviction On Jilin Aodong Pharmaceutical Group Co., Ltd. (SZSE:000623) Even After 36% Share Price Boost

Oct 01
Market Might Still Lack Some Conviction On Jilin Aodong Pharmaceutical Group Co., Ltd. (SZSE:000623) Even After 36% Share Price Boost

A Look At The Intrinsic Value Of Jilin Aodong Pharmaceutical Group Co., Ltd. (SZSE:000623)

Aug 22
A Look At The Intrinsic Value Of Jilin Aodong Pharmaceutical Group Co., Ltd. (SZSE:000623)

Jilin Aodong Pharmaceutical Group (SZSE:000623) Is Increasing Its Dividend To CN¥0.60

Jul 05
Jilin Aodong Pharmaceutical Group (SZSE:000623) Is Increasing Its Dividend To CN¥0.60

Investors Holding Back On Jilin Aodong Pharmaceutical Group Co., Ltd. (SZSE:000623)

Jun 03
Investors Holding Back On Jilin Aodong Pharmaceutical Group Co., Ltd. (SZSE:000623)

There Might Be More To Jilin Aodong Pharmaceutical Group's (SZSE:000623) Story Than Just Weak Earnings

Apr 23
There Might Be More To Jilin Aodong Pharmaceutical Group's (SZSE:000623) Story Than Just Weak Earnings

Earnings and Revenue Growth Forecasts

SZSE:000623 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/20243,0051,430-74306N/A
6/30/20243,278934-160333N/A
3/31/20243,5231,118-164286N/A
12/31/20233,4491,460-35168N/A
9/30/20233,3092,175-26494N/A
6/30/20233,2012,349-157101N/A
3/31/20233,0192,20735299N/A
1/1/20232,8681,781153424N/A
9/30/20222,618968-100171N/A
6/30/20222,4711,313-21692N/A
3/31/20222,4171,448-46262N/A
1/1/20222,3041,78112325N/A
9/30/20212,2341,898-55231N/A
6/30/20212,2131,65145324N/A
3/31/20212,3071,77225296N/A
12/31/20202,2521,709163390N/A
9/30/20202,3461,748318549N/A
6/30/20202,5671,552407600N/A
3/31/20202,7341,087275450N/A
12/31/20193,0881,404157379N/A
9/30/20193,2861,19934221N/A
6/30/20193,3861,19987275N/A
3/31/20193,4391,2550302N/A
12/31/20183,324935102348N/A
9/30/20183,3861,390184428N/A
6/30/20183,3321,560N/A371N/A
3/31/20183,1831,770N/A273N/A
12/31/20172,9771,863N/A256N/A
9/30/20172,8691,754N/A277N/A
6/30/20172,7451,739N/A281N/A
3/31/20172,6701,721N/A361N/A
12/31/20162,7371,666N/A334N/A
9/30/20162,5431,857N/A379N/A
6/30/20162,4131,772N/A416N/A
3/31/20162,3782,370N/A374N/A
12/31/20152,3352,594N/A388N/A
9/30/20152,2412,515N/A422N/A
6/30/20152,2442,530N/A315N/A
3/31/20152,2411,767N/A325N/A
12/31/20142,2401,411N/A289N/A
9/30/20142,2711,274N/A171N/A
6/30/20142,2271,175N/A267N/A
3/31/20142,0911,097N/A209N/A
12/31/20131,9571,059N/A201N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 000623's forecast earnings growth (38.1% per year) is above the savings rate (2.8%).

Earnings vs Market: 000623's earnings (38.1% per year) are forecast to grow faster than the CN market (25.5% per year).

High Growth Earnings: 000623's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 000623's revenue is forecast to grow faster than the CN market.

High Growth Revenue: Insufficient data to determine if 000623's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 000623's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 03:15
End of Day Share Price 2024/12/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jilin Aodong Pharmaceutical Group Co., Ltd. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Weina JiangEverbright Securities Co. Ltd.
Lei PanGuodu Securities Co.
null Research DepartmentGuotai Junan International Holdings Limited